• hiPSC-Derived Intestinal Organoids Advance Pharmacokinetic M

  2026-04-15

  This study presents a streamlined protocol to generate human induced pluripotent stem cell (hiPSC)-derived intestinal organoids, offering improved reproducibility and physiological relevance for pharmacokinetic studies. The findings address current limitations in in vitro drug absorption and metabolism assays, enabling more accurate evaluation of orally administered compounds.

• EZH2 Inhibition and 5-Azacytidine Restore Immunity in PTEN-D

  2026-04-14

  This study demonstrates that dual epigenetic targeting with EZH2 inhibition and 5-azacytidine synergistically overcomes immune evasion in PTEN-deficient glioblastoma by restoring the ERV-MAVS-IFN viral mimicry pathway. The findings highlight a rational combination strategy to remodel the tumor microenvironment and enhance antitumor immunity in resistant gliomas.

• Mapping GCGR Small Molecule Binding: Insights from MK 0893 C

  2026-04-13

  Wang et al. (2024) integrate GCGR crystal structures and molecular dynamics to identify and validate inferential binding sites for small-molecule antagonists, using MK 0893 as the structural benchmark. Their findings clarify the site diversity and binding stability of clinical GCGR antagonists, guiding future type 2 diabetes drug discovery.

• 5-Azacytidine in Precision DNA Demethylation: Translational

  2026-04-13

  Explore the multifaceted role of 5-Azacytidine as a DNA demethylation agent with a focus on translational research value and protocol guidance. This article delivers a unique perspective by bridging clinical epigenetics breakthroughs with advanced laboratory assay optimization.

• BMX Kinase Modulates Lysosomal Acidification in Tuberculosis

  2026-04-12

  A recent Nature Communications study uncovers how Mycobacterium tuberculosis (Mtb) manipulates host cell lysosomal acidification to enhance its intracellular survival by exploiting BMX kinase-mediated phosphorylation of ATP6V1E1. This mechanistic insight opens new avenues for host-directed therapies and provides a foundation for evaluating BMX kinase inhibitors in infection models.

• Angiotensin III: Precision RAAS Peptide for Cardiovascular R

  2026-04-12

  APExBIO's Angiotensin III (human, mouse) empowers cardiovascular and neuroendocrine research with unmatched purity and reproducibility. Discover evidence-driven workflows, advanced assay innovation, and actionable troubleshooting tips for robust RAAS pathway interrogation.

• Leucovorin Calcium in Assembloid Workflows: Protocols & Pitf

  2026-04-11

  Leucovorin Calcium advances antifolate resistance research by enabling precise rescue of normal cells in patient-derived gastric cancer assembloid models. This guide details experimental workflows, troubleshooting strategies, and key innovations that empower translational oncology studies.

• Optimizing Reporter Assays with mCherry mRNA: Protocols & In

  2026-04-11

  EZ Cap™ mCherry mRNA (5mCTP, ψUTP) enables robust, immune-evasive red fluorescence for high-throughput reporter assays and advanced cell imaging. Discover how its Cap 1 structure and nucleotide modifications drive superior stability and translation versus conventional mRNA, and leverage expert workflow tips to maximize reproducibility and signal clarity.

• Disodium (R)-2-Hydroxyglutarate: Technical Use in Cancer Mod

  2026-04-10

  Disodium (R)-2-Hydroxyglutarate is a high-purity biochemical reagent for studies involving inhibition of α-ketoglutarate-dependent dioxygenases and ATP synthase, particularly in the context of IDH1/IDH2 mutant cancer models and energy metabolism. It is not recommended for non-aqueous workflows or applications requiring solvent flexibility, due to its solubility and stability profile.

• Angiotensin III (human, mouse): Mechanistic Leverage and ...

  2026-04-10

  This thought-leadership article explores Angiotensin III (human, mouse), a high-purity RAAS peptide from APExBIO, as a linchpin for advanced cardiovascular, neuroendocrine, and viral pathogenesis research. Integrating mechanistic insights—including its unique receptor interactions, potent aldosterone-stimulating and pressor activity, and emerging roles in SARS-CoV-2 spike protein binding—this guide delivers actionable strategies and visionary perspectives for translational researchers. It contextualizes Angiotensin III within the evolving scientific landscape, escalates the discussion beyond conventional product pages, and empowers innovative, reproducible investigations.

• Solving Lab Assay Challenges with Methyl-β-cyclodextrin (...

  2026-04-09

  This scenario-driven article guides biomedical researchers in overcoming common pitfalls in cell-based assays and membrane studies using Methyl-β-cyclodextrin (SKU C6939). Integrating quantitative data, vendor comparisons, and practical optimization tips, it demonstrates why APExBIO’s reagent is a reliable, high-purity choice for reproducible cholesterol extraction and lipid raft disruption.

• 5-Azacytidine in Cancer Epigenetics: Precision Mechanisms...

  2026-04-08

  Explore the advanced mechanistic insights of 5-Azacytidine as a DNA methyltransferase inhibitor for epigenetic modulation in cancer research. This article delivers a deep scientific analysis of ATR-mediated DNA damage, apoptosis induction, and novel research applications, offering unique value beyond existing literature.

• Angiotensin III (human, mouse): Mechanistic Insights for ...

  2026-04-08

  Angiotensin III (human, mouse) is a highly pure RAAS peptide that mediates pressor and aldosterone effects via AT1 and AT2 receptors. As a precise tool for cardiovascular and neuroendocrine research, its defined action profile and robust quality control distinguish it from related peptides. This article presents atomic, referenced facts for experimental and translational applications.

• Annexin V-Cy5/DAPI Apoptosis Kit: Precision Detection of ...

  2026-04-07

  The Annexin V-Cy5/DAPI Apoptosis Kit offers a rapid, sensitive method for differentiating apoptosis from necrosis in cell populations. This kit supports high-confidence programmed cell death detection, which is essential for cancer and neurodegenerative research. APExBIO’s solution is validated by peer-reviewed evidence and scenario-driven benchmarking studies.

• Strategically Harnessing Methyl-β-cyclodextrin for Next-G...

  2026-04-07

  This thought-leadership article bridges mechanistic understanding and translational strategy for researchers utilizing Methyl-β-cyclodextrin (MβCD) in membrane biology and nanomedicine. Integrating recent findings on nanoparticle elasticity and size in endocytosis, the article provides actionable guidance for optimizing membrane cholesterol extraction, lipid raft disruption, and innovative drug delivery platforms. APExBIO’s high-purity MβCD is contextualized as a pivotal reagent for advancing experimental design and therapeutic translation.

10130 records 1/676 page Next 12345 下5页 Last page